Recent in vitro experiments have unveiled the potential for dendritic cell-based immunotherapy, activated through the CD40/CD40 ligand (CD40L) immune checkpoint, to provoke robust anti-tumor responses not only in CRC [13], but also in hepatocellular carcinoma [14] and oral cancer [15]. Here, CD40LG is linked to hepatocellular carcinoma.